Xinlay FDA Approval Status

FDA Approved: No
Brand name: Xinlay
Generic name: atrasentan
Company: Abbott
Treatment for: Prostate Cancer

Xinlay (atrasentan) is a selective endothelin-A receptor antagonist intended for the treatment of hormone-refractory prostate cancer (HRPC).

In October 2005, Abbott received a not-approvable letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the oral investigational agent Xinlay. The FDA’s Oncologic Drugs Advisory Committee (ODAC) recommended against the approval of Xinlay in September 2005.

Development timeline for Xinlay

Date	Article
Sep 13, 2005	FDA Advisory Committee Does Not Recommend Approval of Xinlay (atrasentan)
Feb 11, 2005	FDA Agrees to File Abbott's New Drug Application for Xinlay (Atrasentan) to Treat Metastatic Hormone-Refractory Prostate Cancer
Dec 14, 2004	Abbott Submits New Drug Application to U.S. FDA for Advanced Prostate Cancer Drug, Xinlay (atrasentan)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer